One of Regenative Labs’ goals is to give patients with articular cartilage defects more options for a longer work-life expectancy and less pain—whether physical or monetary—in their quest to restore their health. This information is relevant to those facing knee issues.
“The results of the use of these allografts for those facing defects in articular cartilage have been staggering. While tissue allografts don’t treat, cure, or prevent any disease or condition, structural tissue allografts are routinely used to replace missing or damaged tissue in the body. We’re just beginning to understand the potential of these allografts for other applications in orthopedic pathology,” said Regenative Labs CEO, Tyler Barrett.
Currently, there are 33 million adults in the United States living with osteoarthritis (OA) and that number continues to grow, with an expected near doubling within the next decade.1 Adults aged 45 to 64, will represent a third of all cases within the next 10 years.2 Untreated osteoarthritis can lead to complications that shorten the lifespan of the patient by six to seven years.
One of the most common solutions to osteoarthritis is total knee arthroplasty (TKA) with monetary costs ranging from anywhere between $12,400-$16,000.3 In addition to the monetary setback, those who work desk jobs take around 4-6 weeks off to recover. If their job requires travel, walking or lifting, they will not be able to perform those job tasks for up to 3 months. Full recovery can take anywhere from 6 months to a whole year. Another option that patients typically look into is an intra-articular corticosteroid injection. Adverse joint effects after an intra-articular corticosteroid (IACS) injection can include, but are not limited to, accelerated OA progression, subchondral insufficiency fracture, complications of osteonecrosis, and rapid joint destruction with bone loss. It is estimated that job-related losses due to complications surrounding defects associated with OA are between $3.4 and $13.2 billion per year.4
Because some of the most common solutions to osteoarthritis create new problems, Regenative Labs has sought to find alternatives to total knee arthroplasty (TKA). One of the ways that Regenative Labs seeks to provide alleviation to patients suffering from articular cartilage defects with its Wharton’s Jelly allograft product.
“Utilizing multiple Wharton’s Jelly derived products over the last five years, I have seen positive patient results,” shared Dr. Javier Carles M.D., Palmetto Clinics of the Carolinas.
As the amount of data increases, the versatility of Wharton’s Jelly allografts and what can be done for patients increases. Since this study was announced, multiple papers have been published in peer reviewed journals on the data gathered on the use of Wharton’s Jelly applications.
“The proof is in patients’ results, including reevaluations, post-application and x- rays,” said Dr. Carles.”
Regenative Labs is continuing to recruit doctors to take part in prospective studies, independent research, and its ongoing retrospective depository.
“We’re committed to continuously improving the standard of care for the regenerative medicine community and facilitating the most clinically relevant patient outcomes,” Barrett continued.